ライフサイエンスコーパス: N-omega-nitro-L-arginine methyl ester

1 s well as when NO synthesis was inhibited by N(omega)-nitro-l-arginine methyl ester.

2 ent with the nitric oxide synthase inhibitor N(omega)-nitro-L-arginine methyl ester.

3 e was abolished by chronic administration of N(omega)-nitro-L-arginine methyl ester.

4 til inhibition of nitric oxide synthase with N(omega) -nitro-l-arginine methyl ester.

5 10(-5) mol/L), a transcription inhibitor; or N(omega)-nitro-L-arginine methyl ester (10(-4) mol/L), a

6 Pretreatment with N omega-nitro-L-arginine methyl ester (100 micromol/L in

7 ion with the nitric oxide synthase inhibitor N omega-nitro-L-arginine methyl ester (11.2 +/- 3.7% inc

8 tors N(omega)-nitro-L-arginine (10 mg/kg) or N(omega)-nitro-L-arginine methyl ester (20 mg/kg) and th

9 olus of the nitric oxide synthase inhibitor, N omega-nitro-L-arginine methyl ester (25 mg/kg), after

10 N(omega)-nitro-L-arginine methyl ester (30 microM) parti

11 retreated with a nonselective NOS inhibitor (N(omega)-nitro-L-arginine methyl ester; 30 mg/kg), a sol

12 ment with a nitric oxide synthase inhibitor (N-omega-nitro-L-arginine methyl ester, 50 mg/kg/day) or

13 Moreover, l-NAME (N(omega)-nitro-l-arginine-methyl ester), a specific inhi

14 N(omega)-nitro-l-arginine methyl ester abolished the sys

15 ot differ significantly between groups after N omega-nitro-L-arginine methyl ester administration.

16 The inhibition of eNOS with N-omega-nitro-L-arginine methyl ester also potently redu

17 (NOS) inhibitors 7-nitroindazole (7-NI) and N-omega-nitro-L-arginine methyl ester also reduced NMDA

18 signal regulated kinase (ERK) inhibitor, and N(omega)-nitro-L-arginine methyl ester, an antagonist of

19 ose-induced NOX4 expression was abrogated by N(omega)-nitro-l-arginine methyl ester, an inhibitor of

20 However, intracerebroventricular infusion of N(omega)-nitro-L-arginine methyl ester, an inhibitor of

21 N(omega)-Nitro-L-arginine methyl ester and 1H-[1,2,4]-ox

22 ence of the nitric oxide synthase inhibitors N-omega-nitro-L-arginine methyl ester and S-methyl-thioc

23 red blood pressure with radiotelemetry after N-omega-nitro-L-arginine-methyl ester and a high salt di

24 -DAMP, charybdotoxin or BAPTA-AM, but not by N(omega)-nitro-L-arginine methyl ester, glipizide, indom

25 arterioles pretreated with ceramide, whereas N(omega)-nitro-l-arginine methyl ester had no effect.

26 N(omega)-Nitro-L-arginine methyl ester, HOE-140, and dic

27 epeated hypertensive challenges using either N(omega)-nitro-L-arginine methyl ester hydrochloride (L-

28 mouse model (induced by a high-fat diet plus N(omega)-nitro-L-arginine methyl ester hydrochloride [L-

29 c oxide production by oral administration of N(omega)-Nitro-L-arginine methyl ester hydrochloride, an

30 In the presence of DTT and the NO inhibitor N(omega)-nitro-L-arginine methyl ester hydrochloride, th

31 ing nitric oxide (NO) synthesis with L-NAME (N(omega)-nitro-L-arginine methyl ester hydrochloride; 5

32 y the competitive inhibitor of NO synthesis, N omega-nitro-L-arginine methyl ester, indicating that A

33 Mechanistically, blockade of eNOS with N(omega)-nitro-L-arginine methyl ester ( L-NAME) abolish

34 with a nitric oxide (NO) synthase inhibitor, N omega-nitro-L-arginine methyl ester (L-NAME) or 7-nitr

35 demand after the systemic administration of N omega-nitro-L-arginine methyl ester (L-NAME) or N omeg

36 NOS inhibitors 7-nitroindazole (7-NI) and N omega-nitro-L-arginine methyl ester (L-NAME) produced

37 Furthermore, (100 mumol/L) N omega-nitro-L-arginine methyl ester (L-NAME), a nitric

38 ine and the nitric oxide synthase inhibitor, N omega-nitro-L-arginine methyl ester (L-NAME), an incre

39 d NG-monomethyl-L-arginine (L-NMMA), but not N omega-nitro-L-arginine methyl ester (L-NAME), trans-st

40 1-arginine, indomethacin, meclofenamate, or N omega-nitro-L-arginine methyl ester (L-NAME).

41 nitric oxide (NO) was inhibited by 10(-4) M N omega-nitro-L-arginine methyl ester (L-NAME).

42 0(-5) mol/L; a cyclooxygenase inhibitor) and N omega-nitro-L-arginine methyl ester (L-NAME, 10(-4) mo

43 N omega-nitro-L-argininel-NA; 100 microM) or N omega-nitro-L-arginine methyl ester (L-NAME; 100 micro

44 and systemic inhibition of endogenous NO by N omega-nitro-L-arginine methyl ester (L-NAME; 100 mumol

45 At 190 mins, N omega-nitro-L-arginine methyl ester (L-NAME; 10mg/kg)

46 N omega-Nitro-L-arginine-methyl-ester (L-NAME) augmented

47 Pretreatment with N(omega)-nitro-l-arginine methyl ester (l-NAME) (10(-3)

48 o to 25 mM, but was unaffected by 100 microM N(omega)-nitro-L-arginine methyl ester (L-NAME) (68 +/-

49 was completely abolished in the presence of N(omega)-nitro-L-arginine methyl ester (L-NAME) (a nitri

50 ivity and, conversely, blockade of NOS using N(omega)-nitro-l-arginine methyl ester (l-NAME) inhibite

51 treated for 3.5 hours with 3 mM ATP or 2 mM N(omega)-nitro-L-arginine methyl ester (L-NAME) or 50 mi

52 rats was determined after administration of N(omega)-nitro-L-arginine methyl ester (L-NAME) or salin

53 N(omega)-nitro-L-arginine methyl ester (L-NAME), an inhi

54 e substantially increased in the presence of N(omega)-nitro-L-arginine methyl ester (L-NAME), an inhi

55 arts generated 3 times more superoxide by an N(omega)-nitro-L-arginine methyl ester (L-NAME)-inhibita

56 of constitutive nitric oxide synthase using N(omega)-nitro-L-arginine methyl ester (L-NAME)-recapitu

57 ular response to long-term NOS inhibition by N(omega)-nitro-L-arginine methyl ester (L-NAME).

58 e increased significantly in the presence of N(omega)-nitro-L-arginine methyl ester (L-NAME).

59 Administration of N(omega)-nitro-L-arginine methyl ester (L-NAME; 20 mg/kg

60 ith either PBS or the NOS inhibitors ADMA or N(omega)-nitro-L-arginine methyl ester (L-NAME; each 250

61 Inhibition of NOS with N(omega)-nitro-L-arginine-methyl ester (L-NAME) signific

62 Prior treatment of the ganglia with N-omega-nitro-L-arginine methyl ester (L-NAME), a nitric

63 to the left hindpaw to block CGRP responses; N-omega-nitro-l-arginine methyl ester (L-NAME), a nonsel

64 ith native LDL in the absence or presence of N-Omega-nitro-L-arginine methyl ester (L-NAME), a specif

65 travenously) with the NO synthase inhibitor, N-omega-nitro-L-arginine methyl ester (L-NAME), or the c

66 Nitric oxide synthase inhibitor, N-omega-nitro-L-arginine methyl ester (L-NAME, 3x10(-4)

67 xyl (TEMPOL,a superoxide dismutase-mimetic), N-omega-nitro-L-arginine methyl ester (L-NAME, a nitric

68 re measured before and during NO inhibition (N(omega)-nitro-l-arginine methyl ester [L-NAME]).

69 e have earlier shown that inhibitors of NOS (N(omega)-nitro-L-arginine methyl ester [L-NAME], 7-nitro

70 (Pe), sodium nitroprusside (Snp) with Pe, or N omega-nitro-L-arginine methyl ester (Lnam).

71 diator or NO released despite treatment with N(omega)-nitro-L-arginine methyl ester, N(omega)-nitro-L

72 utaneous administration of 10 micrograms/min N omega-nitro-L-arginine methyl ester (NAME) for 48 hour

73 ffects were totally reversed by provision of N(omega)-nitro-L-arginine methyl ester (NAME) in arginin

74 L-NAME (N(omega)-nitro-L-arginine methyl ester; nitric oxide syn

75 and O2 consumption in vitro were blocked by N omega-nitro-L-arginine methyl ester or N omega-nitro-L

76 t not by the nitric-oxide synthase inhibitor N(omega)-nitro-L-arginine methyl ester or by the vanillo

77 ith the nitric oxide (NO) synthase inhibitor N(omega) -nitro-l-arginine methyl ester (P > 0.05), indi

78 N(omega)-nitro-l-arginine methyl ester reduced vasodilat

79 tion of the nitric oxide synthase inhibitor, N omega-nitro-L-arginine methyl ester, reverses the vaso

80 nted eNOS glutathionylation and eNOS-derived N(omega)-nitro-L-arginine methyl ester-sensitive superox

81 After the administration of N omega-nitro-L-arginine methyl ester, systemic vascular

82 Pretreatment with N omega-nitro-L-arginine methyl ester to block NO synthe

83 Furthermore, N(omega)-nitro-L-arginine methyl ester-treated or eNOS-d

84 FD+L-NAME (ad libitum high-fat diet and 0.5% N[omega]-nitro-L-arginine methyl ester), we observe that